The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | Mutational burden at relapse following exposure to high dose melphalan in multiple myeloma
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, discusses an investigation into mutational burden at relapse following exposure to high dose melphalan (HDM) compared to no exposure in the tumors of patients with multiple myeloma (MM). Exposure to HDM increases the risk of developing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) (MDS/AML), particularly in patients with MM. Similar to what has been observed in patients with MDS/AML, mutational burden was significantly higher in patients who had been exposed to HDM. However, the outcome of this was not detrimental, suggesting the mutational burden may generate some immunogenicity. Although a progression-free survival (PFS) advantage was not observed with HDM, an overall-survival (OS) benefit was observed. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
